There’s a lot of competition in the regulatory T cells (Tregs) space and that’s a sign that something good is happening. Sonoma Biotherapeutics Inc. CEO Jeff Bluestone likened it to a typical drive leading to an everyday observation.
Privately held Sonoma Biotherapeutics Inc. plans to take its newly raised $40 million series A financing to develop regulatory T-cell therapies to control inflammatory responses in autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.